SHORT COMMUNICATIONCost-effectiveness of thrombotic thrombocytopenic purpura diagnosis: a retrospective analysis in the University Hospital Center of Lyon (France)Jousselme, Emiliea; Sobas, Frédérica; Guerre, Pascaleb; Simon, Mariec; Nougier, Christophea Author Information aService d’Hématologie Biologique – Laboratoire d’Hémostase Hospices Civils de Lyon - Centre de Biologie et Pathologie Est -Groupement Hospitalier Est - Bat A3 - 59, Boulevard Pinel, Bron Cedex bService d’Evaluation Economique en Santé – Cellule Innovation, Hospices Civils de Lyon – 162 Avenue Lacassagne cService de Médecine Intensive-Réanimation –Hôpital Edouard Herriot - Place d’Arsonval, Lyon Cedex 03, France Correspondence to Dr Emilie Jousselme, Laboratoire d’Hématologie Biologique Hospices Civils de Lyon - Centre de Biologie et Pathologie Est -Groupement Hospitalier Est - Bat A3 - 59, Boulevard Pinel, 69677 Bron Cedex, France Tel: +33 0 4 27 85 65 91; e-mail: [email protected] Received 27 March, 2021 Revised 28 June, 2021 Accepted 9 July, 2021 Blood Coagulation & Fibrinolysis: March 2022 - Volume 33 - Issue 2 - p 119-123 doi: 10.1097/MBC.0000000000001071 Buy Metrics Abstract The aim of the present study was to perform an economic evaluation of two alternative assays of ADAMTS13 activity (A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats, member 13) for diagnosing thrombotic thrombocytopenic purpura (TTP) in the Hospital of Lyon (France). The study approach was more economic than clinical. We retrospectively calculated the prescription costs of ADAMST13 activity from January to December 2019 for patients depending on the assay: manual ELISA (Technozym) or automated assay (AcuStar Werfen, Instrumentation Laboratory). Then, we compared the cost of therapeutic plasma exchange (TPE) consumption awaiting ADAMTS13 activity assay results. From an economic point of view, the automated assay was more cost-effective. From a clinical one, we supposed that the faster results given by AcuStar could improve patient care by reducing the number of TPEs. Automated assay could improve patient care without increasing costs in our institution. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.